A shared Indica News piece looks at where current research stands on GLP-1 agonist drugs. Details are in the full article.
Recap by typeshit. Post by Facebook on Facebook.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
An AI chatbot answer lays out single, dual and triple agonists, noting Lilly's retatrutide adds the glucagon receptor and is still investigational.
Nausea hit 20% of users vs 6% on placebo, with other gut effects near placebo levels. A GP tells Medical News Today phase 3 data is still needed.
Loading…